NCT05739045招募中2 期
A Multicenter, Prospective, Phase Ⅱ Clinical Study of Nivolumab Combined With SOX in the Perioperative Treatment of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Xiangdong Cheng1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2022年11月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- pathological complete response rate (pCR)
研究概览
简要总结
To evaluate the pathological complete response rate (pCR) of nivolumab combined with SOX (oxaliplatin + S-1) for neoadjuvant therapy of resectable gastric and gastroesophageal junction adenocarcinoma;
详细描述
Primary Objective
- To evaluate the pathological complete response rate (pCR) of nivolumab combined with SOX (oxaliplatin + S-1) for neoadjuvant therapy of resectable gastric and gastroesophageal junction adenocarcinoma; Secondary Objectives
- To evaluate the major pathological response rate (mPR), R0 resection rate, lymph node status after neoadjuvant therapy (ypN stage), 3-yr-DFS, OS, and safety and tolerability of nivolumab combined with SOX in the periopera; Exploration for markers of benefit groups
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all of the following inclusion criteria to be enrolled in the study:
- •Patients voluntarily participate in the study and sign the informed consent form;
- •Age ≥ 18 years and ≤ 75 years;
- •Have pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma;
- •Patients with gastric or gastroesophageal junction adenocarcinoma at the clinical staging of cT3-4 or N+, M0 (staging according to AJCC version 8) who could be radically resected as determined by CT and laparoscopy;
- •Have not received anti-tumor therapy (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.);
- •Planned surgical treatment after completion of neoadjuvant therapy;
- •Able to swallow tablets normally;
- •ECOG score 0-1;
- •Expected survival >=12 months;
- •Main organ functions normal, i.e., meeting the criteria below:
- •Blood routine examination criteria shall meet:
- •(No blood transfusion or blood products within 14 days, no G-CSF or other hematopoietic stimulating factors are used for correction) Absolute neutrophil count ≥1.5×109/L; Platelet ≥80×109/L; Hemoglobin ≥ 80 g/L
- •Criteria for biochemical tests:
- •Total bilirubin <1.5×ULN; ALT and AST≤2.5×ULN;
- •Serum Cr ≤ 1.5 × ULN or endogenous creatinine clearance > 50 ml/min (males: Endogenous creatinine clearance rate = ((140-age) × body weight)/(72 × serum Cr); female: endogenous creatinine clearance rate = ((140-age) × body weight)/(72 × serum Cr) × 0.85; body weight unit: kg; serum Cr unit: mg/mL):
- •Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and be willing to use a highly effective method of contraception during the trial and for 120 days after the last dose. Male subjects with partners of childbearing potential should be surgically sterilized or agree to use highly effective methods of contraception during the trial and for 120 days after the last dose;
排除标准
- •Patients with any of the following are not to be enrolled in the study:
- •Patients with unresectable factors, including unresectable tumor causes or unresectable surgical contraindications or refusal of surgery;
- •Previous or concurrent other malignancy;
- •Suffering from any chronic or major illness considered intolerable to treatment (eg, severe cardiac disease, uncontrolled hypertension, some degree of hepatic or renal dysfunction, etc.)
- •Patients who have previous gastrointestinal perforation, abdominal abscess or recent (within 3 months) intestinal obstruction or imaging and clinical symptoms suggestive of intestinal obstruction;
- •Patients having clinically significant bleeding symptoms or definite bleeding tendency within 3 months before the first dose of study drug, such as gastrointestinal bleeding, hemorrhagic gastric ulcer or suffering from vasculitis; if stool occult blood is positive at baseline, reexamination may be performed; if stool occult blood remains positive after reexamination, gastroscopy is required (except for patients having gastroscopy within 3 months before enrollment to exclude such condition);
- •Patients in the active stage of infection requiring treatment (such as antibacterial drugs, antiviral drugs, antifungal drugs);
- •Active hepatitis (hepatitis B reference: HBsAg positive and HBV DNA ≥ 500 IU/ml; hepatitis C reference: HCV antibody positive and HCV viral copy number > upper limit of normal);
- •Patients with congenital or acquired immunodeficiency (such as HIV infection);
- •Patients with any active autoimmune disease or history of autoimmune disease with potential relapse;
- •Planned or previous organ or allogeneic bone marrow transplant;
- •Patients with current interstitial pneumonia or interstitial lung disease, or previous history of interstitial pneumonia or interstitial lung disease requiring steroids, or subjects with active pneumonia or severe lung function impairment on screening CT; active pulmonary tuberculosis;
- •Ongoing or recent treatment with immunosuppressive drugs or systemic corticosteroids to achieve immunosuppression;
- •Patients who have received a live attenuated vaccine within 28 days prior to the first dose of study drug or who require administration of such vaccine during treatment or within 60 days after the last dose;
- •Patients with known hypersensitivity to any of the study drugs or any of their excipients;
- •Nursing mothers;
- •Any factors that, in the judgment of the investigator, could affect patient safety and force the termination of the study
研究组 & 干预措施
nivolumab combined with SOX
Experimental
Medication regimen: nivolumab + SOX (3 cycles) before surgery → radical surgery (D2) → nivolumab + SOX (3 cycles) after surgery → nivolumab monotherapy maintenance (11 cycles); Surgery is performed 2 - 6 weeks after the last dose of neoadjuvant therapy, and postoperative adjuvant therapy is initiated at least 4 weeks after surgery.
干预措施: nivolumab combined with SOX (Drug)
结局指标
主要结局
pathological complete response rate (pCR)
时间窗: 3 months
pCR
次要结局
- 3-year DFS(3 years)
研究者
Xiangdong Cheng
Professor
Zhejiang Cancer Hospital
研究点 (1)
Loading locations...
相似试验
撤回
2 期
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseCirculating Tumor DNANon-Small-Cell Lung CarcinomaNon-Small Cell Lung CancerNCT03770299Bristol-Myers Squibb
已完成
1 期
Combination Chemotherapy in Treating Young Patients With Advanced Solid TumorsChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Embryonal TumorChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorRecurrent Childhood Brain Stem GliomaRecurrent Childhood Central Nervous System Embryonal TumorUnspecified Childhood Solid Tumor, Protocol SpecificNCT00281944National Cancer Institute (NCI)42
招募中
2 期
Phase 2 study of CapeOX plus nivolumab for patients with early relapsed gastric cancerGastric CancerJPRN-jRCTs031220572Arai Hiroyuki92
Unknown
2 期
Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.Previously Treated Metastatic Non-Small Cell Lung CancerNCT00238849Integrated Community Oncology Network40
招募中
不适用
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma PatientsOverall Response RateNCT06277024Fujian Medical University50